(Q39595048)

13 September 2017

title

IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR. (English)

1 reference

13 September 2017

0 references

0 references

1 reference

M P Roberti

1

1 reference

13 September 2017

M M Barrio

2

1 reference

13 September 2017

A I Bravo

3

1 reference

13 September 2017

Y S Rocca

4

1 reference

13 September 2017

J M Arriaga

5

1 reference

13 September 2017

M Bianchini

6

1 reference

13 September 2017

J Mordoh

7

1 reference

13 September 2017

E M Levy

8

1 reference

13 September 2017

language of work or name

English

0 references

publication date

10 February 2011

1 reference

Breast Cancer Research and Treatment

13 September 2017

published in

1 reference

13 September 2017

volume

130

1 reference

13 September 2017

issue

2

1 reference

13 September 2017

page(s)

465-475

1 reference

describes a project that uses

13 September 2017

IIB-BR-G

0 references

IIB-BR-G-MT

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s10549-011-1360-2

0 references

cites work

Molecular portraits of breast cancer: tumour subtypes as distinct disease entities

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Triple-negative breast cancer: clinical features and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Signal transduction during natural killer cell activation: inside the mind of a killer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Human NK cell education by inhibitory receptors for MHC class I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Expansion of highly cytotoxic human natural killer cells for cancer cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Regulation of NK cell function by human granulocyte arginase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

A potential role for interleukin-15 in the regulation of human natural killer cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Genes that mediate breast cancer metastasis to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Description of a new human breast cancer cell line, IIB-BR-G, established from a primary undifferentiated tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

IL-15/IL-15 receptor biology: a guided tour through an expanding universe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Interleukin-2, interleukin-15, and their roles in human natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

IL-15 is an essential mediator of peripheral NK-cell homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1360-2

10.1007/S10549-011-1360-2

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference